This is especially true considering that other multi-target kinase inhibitors, including imatinib, were previously shown to cause growth failure in children affected with chronic myeloid leukemia primarily by perturbing the GH:IGF-1 axis [34]. The gene discussed is IGF1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.